NASDAQ:PRQR

ProQR Therapeutics (PRQR) Stock Forecast, Price & News

$1.47

-0.01 (-0.68%)

(As of 09/22/2023 ET)

Compare

Today's Range: $1.47
▼
$1.50
50-Day Range: $1.36
▼
$1.77
52-Week Range: $0.72
▼
$3.85

Volume: 90,293 shs
Average Volume: 130,959 shs
Market Capitalization: $118.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.88

ProQR Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 164.2% Upside
$3.88 Price Target
Short Interest: Healthy
1.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.56
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.25) to ($0.38) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

841st out of 963 stocks

Pharmaceutical Preparations Industry

407th out of 455 stocks

3.4

Analyst's Opinion

Consensus Rating
ProQR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.88, ProQR Therapeutics has a forecasted upside of 164.2% from its current price of $1.47.
Amount of Analyst Coverage
ProQR Therapeutics has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.73% of the float of ProQR Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
ProQR Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ProQR Therapeutics has recently decreased by 2.94%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
ProQR Therapeutics does not currently pay a dividend.
Dividend Growth
ProQR Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRQR.

0.8

News and Social Media Coverage

News Sentiment
ProQR Therapeutics has a news sentiment score of -0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for ProQR Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.40% of the stock of ProQR Therapeutics is held by insiders.
Percentage Held by Institutions
Only 26.15% of the stock of ProQR Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.25) to ($0.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ProQR Therapeutics is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ProQR Therapeutics is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ProQR Therapeutics has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

PRQR Price History

30 days | 90 days | 365 days | Advanced Chart

PRQR Stock News Headlines

September 19, 2023 | americanbankingnews.com

ProQR Therapeutics (NASDAQ:PRQR) PT Lowered to $1.80

September 17, 2023 | americanbankingnews.com

ProQR Therapeutics (NASDAQ:PRQR) Lowered to Hold at StockNews.com

September 24, 2023 | Chaikin Analytics (Ad)

Wall Street Legend Warns "Mass Bank Run" is Coming

Man who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.

September 7, 2023 | finance.yahoo.com

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

August 8, 2023 | finance.yahoo.com

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutions

August 4, 2023 | msn.com

Chardan Capital Reiterates ProQR Therapeutics N.V (PRQR) Neutral Recommendation

August 4, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About ProQR Therapeutics

August 3, 2023 | uk.finance.yahoo.com

ProQR Announces Second Quarter 2023 Operating and Financial Results

September 24, 2023 | Chaikin Analytics (Ad)

Wall Street Legend Warns "Mass Bank Run" is Coming

Man who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.

August 2, 2023 | technews.tmcnet.com

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

August 1, 2023 | finance.yahoo.com

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets

July 18, 2023 | finance.yahoo.com

PRQR Oct 2023 7.500 call

June 28, 2023 | stocknews.com

2 Biotech Stocks to Buy, 1 to Sell Now

June 28, 2023 | finance.yahoo.com

ProQR Therapeutics' (NASDAQ:PRQR) investors will be pleased with their impressive 109% return over the last year

May 23, 2023 | markets.businessinsider.com

Chardan Capital Remains a Hold on ProQR (PRQR)

May 18, 2023 | finance.yahoo.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability

May 17, 2023 | msn.com

HC Wainwright & Co. Reiterates ProQR Therapeutics N.V (PRQR) Buy Recommendation

May 17, 2023 | msn.com

JMP Securities Reiterates ProQR Therapeutics N.V (PRQR) Market Outperform Recommendation

May 17, 2023 | msn.com

Analyst Ratings for ProQR Therapeutics

May 17, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for ProQR (PRQR)

May 16, 2023 | msn.com

Recap: ProQR Therapeutics Q1 Earnings

May 16, 2023 | finance.yahoo.com

ProQR Announces First Quarter 2023 Operating and Financial Results

May 9, 2023 | finance.yahoo.com

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

April 20, 2023 | finance.yahoo.com

ProQR Announces Upcoming Investor Conferences in April and May

April 18, 2023 | finance.yahoo.com

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

March 31, 2023 | benzinga.com

ProQR Therapeutics Stock (NASDAQ:PRQR), Earnings Estimates, EPS, and Revenue

March 30, 2023 | markets.businessinsider.com

Positive Report for ProQR (PRQR) from JMP Securities

See More Headlines

Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Company Calendar

Last Earnings: 8/03/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRQR
CUSIP: N/A
CIK: 1612940
Web: www.proqr.com
Phone: (188) 166-7000
Fax: N/A
Employees: 130
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.88
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $1.80
Forecasted Upside/Downside: +164.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.73)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-68,600,000.00
Net Margins: -1,427.27%
Pretax Margin: -1,433.16%
Return on Equity: -86.23%
Return on Assets: -34.38%

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 5.71
Quick Ratio: 5.71

Sales & Book Value

Annual Sales: $4.25 million
Price / Sales: 27.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.85 per share
Price / Book: 1.73

Miscellaneous

Outstanding Shares: 80,820,000
Free Float: 74,028,000
Market Cap: $118.81 million
Optionable: Optionable
Beta: -0.02

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Domenico Valerio Ph.D. (Age 67)
Founder & Independent Chairman of Supervisory Board
Comp: $79.35k

Mr. Daniel Anton de Boer (Age 40)
Founder, CEO & Member of Management Board
Comp: $1.41M

Mr. Rene K. Beukema (Age 59)
Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board
Comp: $315.27k

Dr. Gerard Platenburg (Age 59)
Co-Founder & Chief Scientific Officer

Mr. Jurriaan Dekkers (Age 47)
Chief Financial Officer

Ms. Sheila Sponselee (Age 39)
VP & Head of People and Operations

Ms. Sarah Cue Kiely
VP of Investor Relations & Corp. Communications

Ms. Sandra van der Kolk
Jr. Financial Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PRQR Stock - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PRQR shares.
View PRQR analyst ratings or view top-rated stocks.
What is ProQR Therapeutics' stock price forecast for 2023?: 6 Wall Street research analysts have issued 12-month price targets for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $1.80 to $5.00. On average, they predict the company's share price to reach $3.88 in the next year. This suggests a possible upside of 164.2% from the stock's current price.
View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts.
How have PRQR shares performed in 2023?: ProQR Therapeutics' stock was trading at $3.70 at the beginning of the year. Since then, PRQR shares have decreased by 60.3% and is now trading at $1.47.
View the best growth stocks for 2023 here.
When is ProQR Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our PRQR earnings forecast.
How were ProQR Therapeutics' earnings last quarter?: ProQR Therapeutics (NASDAQ:PRQR) issued its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. The biopharmaceutical company had revenue of $1.31 million for the quarter, compared to analyst estimates of $2.77 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 86.23% and a negative net margin of 1,427.27%.
What ETF holds ProQR Therapeutics' stock ?: Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio.

What other stocks do shareholders of ProQR Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).
What is ProQR Therapeutics' stock symbol?: ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."
Who are ProQR Therapeutics' major shareholders?: ProQR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Marshall Wace LLP (0.38%), Monaco Asset Management SAM (0.29%), Renaissance Technologies LLC (0.25%), JPMorgan Chase & Co. (0.22%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%).
How do I buy shares of ProQR Therapeutics?: Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ProQR Therapeutics' stock price today?: One share of PRQR stock can currently be purchased for approximately $1.47.
How much money does ProQR Therapeutics make?: ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $118.81 million and generates $4.25 million in revenue each year. The biopharmaceutical company earns $-68,600,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.
How many employees does ProQR Therapeutics have?: The company employs 130 workers across the globe.
How can I contact ProQR Therapeutics?: ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.

This page (NASDAQ:PRQR) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ProQR Therapeutics (PRQR) Stock Forecast, Price & News

ProQR Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ProQR Therapeutics (NASDAQ:PRQR) Stock

PRQR Price History

PRQR Stock News Headlines

PRQR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

PRQR Stock - Frequently Asked Questions

Overall MarketRank^™